Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG00011 versus placebo in idiopathic pulmonary fibrosis
NL-OMON46196Phase 2Active, not recruiting
- Sponsor
- Biogen
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing BG00011 with Placebo (2 arms). Primary endpoint: Yearly rate of change in forced vital capacity. Started Oct 2018; status: active, not recruiting.
02
Drugs
STX-100
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON46196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46196.